Eikon Therapeutics, Inc. Common Stock vs. Moderna, Inc. Common Stock
EIKN
Eikon Therapeutics, Inc. Common Stock
$10.83 -1.19%
VS MRNAModerna, Inc. Common Stock
$145.28 -2.41%
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| EIKN | MRNA | |
|---|---|---|
| Market Cap | $593.65 million | $59.43 billion |
| Revenue (TTM) | — | $2.23 billion |
| Net Income (TTM) | — | $-3,151,000,000 |
MRNA leads on 1 of 1 size & scale factors.
Valuation
| EIKN | MRNA | |
|---|---|---|
| Price / Book | 1.27 | 8.79 |
| Price / Sales | — | 26.68 |
EIKN leads on 1 of 1 valuation factors.
Profitability
| EIKN | MRNA | |
|---|---|---|
| Net Margin | — | -141.43% |
| Return on Equity | — | -46.61% |
EIKN and MRNA split the profitability factors evenly.
Risk & Sentiment
| EIKN | MRNA | |
|---|---|---|
| Short Interest | 1.60% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: EIKN overview, EIKN financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.